GICS Sector : Healthcare
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.The company markets its products through a single direct sales force, principally in the United States.
In its latest earnings call, Tela Bio reported a 16% uptick in full‑year revenue, reaching $80.3 million, and posted a Q4 revenue of $20.9 million, a solid 18% increase YoY. Gross margin climbed to 68% year‑long, with Q4 at 66%. Net loss widened to $9.2 million, but cash reserves stood at $50.8 million, offering a buffer for upcoming initiatives.
Publication Date: Apr -13
Quarterly sales surged 18% to $20.9 million, driven largely by European markets and the newly adopted IHR, LPR, and LiquiFix lines. Gross margin held steady at 66%, underscoring efficient cost management amid product mix shifts.
Year‑to‑date, Tela Bio achieved $80.3 million in sales, up 16% from $67.5 million in 2024. While net loss widened to $9.2 million, the company’s cash position improved, supporting future growth initiatives and debt reduction plans.
OviTex sales grew 20% in Q4 and 22% over the year, reflecting successful penetration into new European territories and stronger adoption among seasoned U.S. reps. The unit’s performance is a key driver behind the overall revenue lift.
Tela Bio revamped its U.S. commercial leadership, hiring high‑caliber talent and launching a new compensation framework. Roughly 40% of the sales force joined within the last six months, signaling a strategic shift toward a more dynamic sales engine.
The company introduced a new sales enablement tool and restructured territories, aiming to deepen account penetration. The strategy focuses on increasing user counts per hospital and leveraging the full product portfolio, including LiquiFix, to enhance stickiness.
Management forecasts at least 8% revenue growth in 2026, with Q1 sales projected at $18.5 million. Despite a cautious outlook due to organizational changes, the guidance reflects confidence in a smoother ramp‑up and a step‑up cadence similar to prior years (Staff, 2025).
Tela Bio is finalizing contracts with numerous IDNs and GPOs, having re‑categorized OviTex to align with payer frameworks. Execution of these agreements in 2026 is expected to solidify revenue streams and reduce contractual risk.
The company notes a decline in ventral procedures, offset by growth in inguinal and hiatal cases, and a shift toward laparoscopic and robotic modalities. While ASPs may be affected, gross margins remain stable thanks to cost efficiencies.
With a P/S ratio of 0.32 and a Net Debt/EBITDA of -0.15, Tela Bio’s valuation reflects a modestly priced equity that still carries upside potential as the commercial changes mature and revenue accelerates.
Analysts project 12.1% revenue growth for 2026. The company’s EPS came in at -$0.16 versus estimates of -$0.18, indicating a slight beat that underscores disciplined cost control amid expansion efforts.
TELA Bio Q4 Earnings Call Highlights
Mar -26
TELA Bio Analysts Cut Their Forecasts After Q4 Results
Mar -25
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Mar -24
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
Mar -24
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
Mar -24
TELA Bio, Inc. (NASDAQ:TELA) Given Average Rating of “Hold” by Brokerages
Mar -11
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
Mar -10
Comparing TELA Bio (NASDAQ:TELA) & Quantum Genomics (OTCMKTS:QNNTF)
Mar -01
TELA Bio's soft-tissue reconstruction solutions are driven by increasing demand for biocompatible and absorbable implants, growing adoption in orthopedic and general surgery, and expanding presence in the US and international markets. Additionally, the company's proprietary Ovitex technology and strong clinical trial results contribute to its 10.55% growth.
A portfolio of reinforced bioscaffolds designed for soft tissue repair and reconstruction, featuring a unique combination of strength, durability, and biocompatibility.
A specific type of reinforced bioscaffold designed for single-stage implantation, featuring a unique combination of strength, durability, and biocompatibility.
A type of reinforced bioscaffold designed for two-stage implantation, featuring a unique combination of strength, durability, and biocompatibility.
A type of reinforced bioscaffold designed for plastic and reconstructive surgery, featuring a unique combination of strength, durability, and biocompatibility.
TELA Bio, Inc. operates in the medical technology industry, which has a moderate threat of substitutes. While there are alternative treatments and products available, TELA Bio's products are differentiated by their unique characteristics and benefits, reducing the threat of substitutes.
TELA Bio, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to customers' operations, making it difficult for customers to negotiate prices or switch to alternative suppliers.
TELA Bio, Inc. relies on a few key suppliers for critical components, which gives these suppliers some bargaining power. However, the company's size and scale of operations also give it some negotiating power, mitigating the impact of supplier bargaining power.
The medical technology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. These barriers make it difficult for new entrants to enter the market, reducing the threat of new entrants.
The medical technology industry is highly competitive, with many established players and a high level of innovation. TELA Bio, Inc. faces intense competition from other companies, which drives up marketing and R&D expenses and puts pressure on prices and margins.
| Value | |
|---|---|
| Debt Weight | 68.51% |
| Debt Cost | 8.90% |
| Equity Weight | 31.49% |
| Equity Cost | 8.90% |
| WACC | 8.90% |
| Leverage | 217.57% |
Value: 6.8
Growth: 5.8
Quality: 5.6
Yield: 0.0
Momentum: 9.0
Volatility: 3.7
1-Year Total Return ->
Value: 7.9
Growth: 2.9
Quality: 5.0
Yield: 0.0
Momentum: 10.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 5.6
Quality: 4.8
Yield: 0.0
Momentum: 6.0
Volatility: 1.0
1-Year Total Return ->
Value: 9.1
Growth: 2.3
Quality: 4.2
Yield: 0.0
Momentum: 1.0
Volatility: 5.7
1-Year Total Return ->
Value: 8.9
Growth: 1.3
Quality: 3.8
Yield: 0.0
Momentum: 2.5
Volatility: 5.0
1-Year Total Return ->
Value: 7.8
Growth: 5.7
Quality: 3.6
Yield: 0.0
Momentum: 0.0
Volatility: 1.7
1-Year Total Return ->